When was Praesidium Bioscience founded?

Praesidium Bioscience was founded in 2022.

Where is Praesidium Bioscience located?

Praesidium Bioscience is headquartered in New York City, United States.

How many employees does Praesidium Bioscience have?

As of Apr 30, 2026, the latest employee count at Praesidium Bioscience is 1.

Is Praesidium Bioscience a funded company?

Praesidium Bioscience is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Praesidium Bioscience rank among its competitors?

Praesidium Bioscience ranks 89th amongst 272 active competitors, of which 78 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Helex, which secured $3.5M in Oct, 2025.

Who are the top competitors of Praesidium Bioscience?

Praesidium Bioscience's top competitors include Sirnaomics, Acorda and Aera. Among them, Helex secured the most recent funding round in October, 2025.

Praesidium Bioscience - 2026 Company Profile, Team & Competitors

Company Details

Developer of cellular delivery platform technology for in vivo genetic medicines. The company offers genetically engineered cellular bioreactors to produce living nanoparticles that deliver in vivo mRNA as infectious or cancer vaccines.

Website: www.praesidium.bio/
Email ID: *****@praesidium.bio

Key Metrics

Founded Year

2022

Location

New York City, United States

Stage

Unfunded

Ranked

89^th among 272 active competitors

Employee Count

1 as on Apr 30, 2026

Similar Companies

Sirnaomics & 358 more

View Praesidium Bioscience's full profile

Praesidium Bioscience has not raised any funding rounds yet.

The founders of Praesidium Bioscience is Tom Henley.

Here are the details of Praesidium Bioscience's key team members:

Tom Henley: Co-Founder & Chief Scientific Officer of Praesidium Bioscience.

View details of Praesidium Bioscience's Founder profiles and Board Members

Praesidium Bioscience's employee count trend

Praesidium Bioscience has 1 employees as of Apr 26. Here is Praesidium Bioscience's employee count trend over the years:

Employee count trend for Praesidium Bioscience

Uncover Praesidium Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Praesidium Bioscience include Sirnaomics, Acorda and Aera. Here is the list of Top 10 competitors of Praesidium Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
2nd	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	J P Morgan, Saints Capital & 15 others	65/100
3rd	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Google Ventures, Lux Capital & 2 others	62/100
4th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
5th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
6th	Clene Nanomedicine 2012, Salt Lake City (United States), Public	Developer of therapeutics for the treatment of neurodegenerative diseases	$42.5M	KSV Global, Pulsar Capital Management & 7 others	58/100
7th	Topas Therapeutics 2016, Hamburg (Germany), Series B	Developer of nanoparticle-based therapeutics for immunology disorders	$68.5M	Boehringer Ingelheim Venture Fund, Epidarex Capital ... & 7 others	57/100
8th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	57/100
9th	Nanoform 2008, Helsinki (Finland), Public	Provider of a platform for the development of nano particles	-	Business Finland, SPV Investments	56/100
10th	Aphios 1993, Boston (United States), Funding Raised	Developer of therapeutic products and enabling technology platforms for healthcare	-	National Heart Lung and Blood Institute, NIH ... & 3 others	55/100
89th	Praesidium Bioscience 2022, New York City (United States), Unfunded	Developer of cellular delivery platform technology for in vivo genetic medicines	-	-	28/100